Efficacy of topical blockade of interleukin-1 in experimental dry eye disease - Wikidata - wikimedia - TriplyDB

Efficacy of topical blockade of interleukin-1 in experimental dry eye disease

Efficacy of topical blockade of interleukin-1 in experimental dry eye disease

http://www.wikidata.org/entity/Q36044544

about

Dry eye: an inflammatory ocular disease Design of a superior cytokine antagonist for topical ophthalmic use Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.Establishing PAX6 as a biomarker to detect early loss of ocular phenotype in human patients with Sjögren's syndrome The core mechanism of dry eye disease is inflammation.Dry eye as a mucosal autoimmune disease.Hevin plays a pivotal role in corneal wound healing.Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence.Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease IL-1β promotes corneal epithelial cell migration by increasing MMP-9 expression through NF-κB- and AP-1-dependent pathways.Inflammatory Response to Lipopolysaccharide on the Ocular Surface in a Murine Dry Eye Model.Spdef null mice lack conjunctival goblet cells and provide a model of dry eye.Dry eye modifies the thermal and menthol responses in rat corneal primary afferent cool cells.Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease.Do Cyclosporine A, an IL-1 Receptor Antagonist, Uridine Triphosphate, Rebamipide, and/or Bimatoprost Regulate Human Meibomian Gland Epithelial Cells?What is the value of incorporating tear osmolarity measurement in assessing patient response to therapy in dry eye disease?Lymphatic vessels: new targets for the treatment of inflammatory diseases.An update on dry eye disease molecular treatment: advances in drug pipelines.The eye: a window of opportunity in rheumatoid arthritis?Current Approach to Dry Eye Disease.Ageing and ocular surface immunity.Supercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: comparative study with the conventional cyclosporin A emulsion TRI Microspheres prevent key signs of dry eye disease in a murine, inflammatory model.Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.Dry eye syndrome: developments and lifitegrast in perspective.Reduction of product-related species during the fermentation and purification of a recombinant IL-1 receptor antagonist at the laboratory and pilot scale.Therapeutic inhibitors for the treatment of dry eye syndrome.The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases.MyD88 Deficiency Protects Against Dry Eye–Induced Damage.

P2860

Q26852044-43493019-19C4-4535-B836-A1ACE37F700E Q27676526-4F60B56A-D9A0-4711-86D2-9D19DF27129E Q34206399-E08B723F-C922-4D7E-883A-FA90DCE14787 Q34473772-1141C6D6-37BF-406E-B8F3-10599C07067B Q34510429-8B6D04B8-5DA7-4DFB-B68B-6A74170D8129 Q34647761-9F0AA319-AE48-4479-955D-41EF3CCA7287 Q35058600-1A8F0877-07D9-4C5F-97F8-33AEC3682AF4 Q35570541-F271BA51-FF55-4BA1-92A5-7A157AF57655 Q35907009-760290F3-CA24-48C0-93D6-7A96B741B0CF Q36665694-1AFA279F-51BC-4C01-8BF7-DEFC17B1CC9F Q36872927-B8B7E3DC-44EF-40CE-BD58-178694B86DD2 Q36986476-5ED7BAF0-A55F-46AD-810E-E1AB2CD27FBD Q37054835-1F9681B9-630B-4693-BC0D-634F47B4D867 Q37195776-2F87AD56-154D-492D-B109-EDFEEBA1D25A Q37242107-4EC80BBD-F64E-4C3C-BD53-ECA9641118AB Q37397203-9A0FD06D-35DD-4727-B821-C5A347A1DA9A Q38161374-25FE3AA9-9226-44E3-B429-6A736C437AE6 Q38207723-A4AECCE2-7534-4E15-A5CF-8C42495F00FE Q38219053-76F7BD5C-A6D5-4651-A62A-B07E60483A13 Q38235721-C6E4D3D1-14A0-4069-860C-5D6D2FEB3B62 Q38886086-B77760FD-CA42-472C-99E2-807345D5DAB0 Q42792794-36CC6D67-9E65-4B73-940A-05B6271508AC Q47138569-FED62017-BC4C-439E-A6A7-A6C196A65872 Q47442388-F7CEA6CE-7E9D-4F4C-86F8-30A7658B2EF0 Q47639135-0582114C-3430-464B-8B9D-2269C5F92F96 Q47861500-F1F76C6B-2FE2-4D4B-9A35-46F6B992100A Q50110517-380539E2-2A35-46B5-BB31-B9E45D9930BB Q52768652-4FDC71AF-E06B-4AA6-BDFD-751812900BC0 Q55355486-C5B63D8B-8EED-4332-8DF7-BE4F40D18EB8

P2860

Efficacy of topical blockade of interleukin-1 in experimental dry eye disease

http://www.wikidata.org/entity/Q36044544

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Efficacy of topical blockade of interleukin-1 in experimental dry eye disease

@ast

Efficacy of topical blockade of interleukin-1 in experimental dry eye disease

@en

type

label

Efficacy of topical blockade of interleukin-1 in experimental dry eye disease

@ast

Efficacy of topical blockade of interleukin-1 in experimental dry eye disease

@en

prefLabel

Efficacy of topical blockade of interleukin-1 in experimental dry eye disease

@ast

Efficacy of topical blockade of interleukin-1 in experimental dry eye disease

@en

P1433

Q36044544-75C3D47C-B3C3-45BA-8969-30108CE3A5AF

P1476

Q36044544-667A55C2-DA21-4C8C-BCDB-688526B5D039

P2093

Q36044544-079C5F36-4063-405B-AAE1-DB95001573CE

Q36044544-1861EB70-C9DB-4B5B-8D01-5AFF57DD9FFB

Q36044544-1B7E614B-69AE-40CE-9CE1-DFA6C9023FD1

Q36044544-3E3F4119-F998-46D7-9FD7-9970E6B506CB

Q36044544-4746FD6B-ECBC-40E5-A93C-09D2BD43B5FF

P2860

Q36044544-04D7B749-A80D-481C-A6BC-2ACB82856061

Q36044544-0642CFFB-94B3-4382-AE74-FB45D4C8E732

Q36044544-077F53DE-ABFC-4B15-B986-F906376F13B8

Q36044544-0C8912DD-32E8-4AF0-BA48-C9E34B3A844A

Q36044544-0D222454-B73C-4BE9-8F8A-2B7B71FDD04F

Q36044544-0E4F6F20-51A2-472E-8481-D970B6DD9734

Q36044544-1CCFD74A-0A8B-407D-BCD0-26D7BF8E1677

Q36044544-272D87D6-70F7-41F1-B4E0-146D860B8FD1

Q36044544-2CF9E28F-045A-4A71-9A38-B0D284696455

Q36044544-37E9448C-FF3F-4881-BBCB-915B3A73FACE

P304

Q36044544-CFFA9296-A356-4EC6-A3D7-5B63F7151777

P31

Q36044544-D00FEF4F-6AC1-4182-936A-906847FE6463

P356

Q36044544-13F59CC5-48D8-4AFF-AFD2-111E6D088B0A

P407

Q36044544-DEBC8FE5-A711-4047-BDBC-28BB752EB576

P433

Q36044544-48A37907-62D3-44D3-BCBC-9648E7726CFC

P478

Q36044544-FD8025C4-1983-4789-9DD6-B9BC5E256F51

P577

Q36044544-721ED22B-4A6A-42A2-A8A5-DF94CD9AB31F

P698

Q36044544-05C1EA5F-F837-4622-9EA9-259E5BC266E2

P932

Q36044544-A5B5BB95-729D-479C-A0CF-1F195A89A157

P356

J.AJO.2012.01.034

P1433

American Journal of Ophthalmology

P1476

Efficacy of topical blockade of interleukin-1 in experimental dry eye disease

@en

P2093

Andre Okanobo

http://www.w3.org/2001/XMLSchema#string

Mohammad H Dastjerdi

http://www.w3.org/2001/XMLSchema#string

Reza Dana

http://www.w3.org/2001/XMLSchema#string

Shilpa Kodati

http://www.w3.org/2001/XMLSchema#string

Sunil K Chauhan

http://www.w3.org/2001/XMLSchema#string

P2860

Th17 and regulatory T cells in mediating and restraining inflammation.

Corneal avascularity is due to soluble VEGF receptor-1

Biologic basis for interleukin-1 in disease

Mouse IL-1 receptor antagonist isoforms: complementary DNA cloning and protein expression of intracellular isoform and tissue distribution of secreted and intracellular IL-1 receptor antagonist in vivo.

Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome.

Characterization of effector T cells in dry eye disease.

Curcumin protects against hyperosmoticity-induced IL-1beta elevation in human corneal epithelial cell via MAPK pathways.

Novel characterization of MHC class II-negative population of resident corneal Langerhans cell-type dendritic cells.

Ocular complications of topical, peri-ocular, and systemic corticosteroids.

The corneal stroma is endowed with a significant number of resident dendritic cells.

P304

63-71

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AJO.2012.01.034

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

154

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22541929

http://www.w3.org/2001/XMLSchema#string

P932

3378826

http://www.w3.org/2001/XMLSchema#string